search
Back to results

Study With a Topical Gel to Treat Common Warts in Adults

Primary Purpose

Warts

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Resiquimod
Sponsored by
Graceway Pharmaceuticals, LLC
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Warts focused on measuring Warts, Adults, Common Warts, Resiquimod

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Diagnosis of common warts Two forms of birth control Exclusion Criteria: Pregnant or breast feeding Other types of warts, ie. plantar Currently participating in another clinical study Chronic viral hepatitis B or C

Sites / Locations

  • Minnesota Clinical Study Center

Outcomes

Primary Outcome Measures

Clearance of treated wart(s)

Secondary Outcome Measures

Partial clearance of treated wart(s)

Full Information

First Posted
June 30, 2005
Last Updated
February 16, 2007
Sponsor
Graceway Pharmaceuticals, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT00117871
Brief Title
Study With a Topical Gel to Treat Common Warts in Adults
Official Title
A Two-Stage, Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Adults
Study Type
Interventional

2. Study Status

Record Verification Date
November 2006
Overall Recruitment Status
Completed
Study Start Date
October 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Graceway Pharmaceuticals, LLC

4. Oversight

5. Study Description

Brief Summary
The primary purpose of this study is to evaluate the effectiveness in adults of 2 different strengths of resiquimod gel applied to common wart(s) five times a week for up to 12 weeks. A second purpose is to evaluate the safety of the drug.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Warts
Keywords
Warts, Adults, Common Warts, Resiquimod

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
Single
Allocation
Non-Randomized
Enrollment
48 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Resiquimod
Primary Outcome Measure Information:
Title
Clearance of treated wart(s)
Secondary Outcome Measure Information:
Title
Partial clearance of treated wart(s)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of common warts Two forms of birth control Exclusion Criteria: Pregnant or breast feeding Other types of warts, ie. plantar Currently participating in another clinical study Chronic viral hepatitis B or C
Facility Information:
Facility Name
Minnesota Clinical Study Center
City
Fridley
State/Province
Minnesota
ZIP/Postal Code
55432
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Study With a Topical Gel to Treat Common Warts in Adults

We'll reach out to this number within 24 hrs